Keyphrases
Indonesia
100%
Chemotherapy
100%
Rituximab
100%
Lymphoma Patients
100%
Diffuse Large B-cell Lymphoma (DLBCL)
100%
Cost Budget
100%
Budget Impact Analysis
100%
R-CHOP
100%
Cost-utility
100%
Reduction Scenarios
33%
Direct Medical Costs
33%
Incremental Cost-effectiveness Ratio
33%
Price Reduction
33%
Benefit Package
33%
National Health Insurance
16%
Decision Maker
16%
Cost-effectiveness
16%
Clinical Trials
16%
Effective Therapy
16%
Cost-effective Intervention
16%
Cost Data
16%
Indirect Costs
16%
Discount Rate
16%
Clinical Evidence
16%
Hospital Data
16%
Doxorubicin
16%
GDP per Capita
16%
Health Benefits
16%
Prednisone
16%
National Health System
16%
Societal Perspective
16%
Cost-utility Analysis
16%
Utility Data
16%
Markov Model
16%
Payer Perspective
16%
Budget Impact
16%
Probabilistic Sensitivity Analysis
16%
Financial Implications
16%
Rituximab Plus Cyclophosphamide
16%
Monetary Data
16%
Indirect Utility
16%
Medicine and Dentistry
Health Care Cost
100%
Diffuse Large B-Cell Lymphoma
100%
Rituximab
100%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
75%
Cost-Effectiveness Analysis
37%
Clinical Trial
12%
Lifespan
12%
Head
12%
Doxorubicin
12%
Quality Adjusted Life Year
12%
Cyclophosphamide
12%
Prednisone
12%
Vincristine
12%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Rituximab
100%
Diffuse Large B Cell Lymphoma
100%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
100%
Clinical Trial
16%
Doxorubicin
16%
Cyclophosphamide
16%
Prednisone
16%
Vincristine
16%
Social Sciences
Impact Analysis
100%
Cost-Effectiveness Analysis
100%
Health Economics
66%
National Health Insurance
66%
Decision Maker
33%
Discount Rate
33%
Markov Model
33%
Cost-Utility Analysis
33%
Agricultural and Biological Sciences
B Cell
100%
Rituximab
100%
Head
33%
Cyclophosphamide
33%
Prednisone
33%
Vincristine
33%